Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0153690 (bone metastases)
 6,382 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Forty patients with hypercalcaemia (2.75 to 3.5 mmoles/l) due to bone metastases or to a neoplastic syndrome were treated with synthetic human calcitonin after previous hyperhydration. On entering the study, the patients were allocated at random to either an 0.5 mg dose or a 1 mg dose of the compound administered 6-hourly by the intravenous route. Calcemia was measured every 6 hours: if it became normal, treatment was discontinued 12 hours later, but if after 3 injections the blood calcium level had not been reduced by more than 0.4 mmoles/l, incremental doses of calcitonin were given. Synthetic human calcitonin reduced calcemia by more than 0.4 mmoles/l in 22 patients (group 1) and brought it down to normal value in 18 of these 8 hours on average after the first injection. A new rise in calcemia was observed in 12/18 cases 44 hours on average after treatment was discontinued. Reduction of calcemia by less than 0.4 mmoles/l was observed in 11 patients (group 2). Treatment was ineffective in 7 patients (group 3). There were no significant differences between the 3 groups in mean values and variances of the initial blood calcium levels. Whatever the initial dose of calcitonin, the therapeutic effect was obtained within the first 24 hours of treatment. In patients with incomplete results increasing the dosage did not result in a further reduction of calcemia. No hypocalcaemia was observed. This study confirms that synthetic human calcitonin has a normalizing effect on calcemia. This effect is not dose-dependent, and blood calcium levels rise again after treatment is discontinued.
 ...
PMID:[Human calcitonin in neoplastic hypercalcemia. Results of a prospective randomized trial]. 297 78

Twenty cases of metastatic bone tumors were treated with Elcatonin together with irradiation, achieving pain relief in 47.3% of cases, improved bone scintigrams in 16.7% of cases and radiographic improvement of invaded bone in 7.7% of cases. It has reported that calcitonin is effective for pain relief in 50% of cases but for the radiographic improvement of bone lesions in only 0-10%. The life quality of patients with bone metastases is controversial since treatment techniques for advanced oncological patients has progressed remarkably. The pain relief obtained with calcitonin contributes significantly to improving the quality of life for such patients when administered in combination with conventional treatment modes.
 ...
PMID:[Radiotherapy of metastatic bone tumor with a synthetic calcitonin derivative (Elcatonin) with irradiation]. 298 31

Fourteen cases of urogenital tumors (9 prostatic carcinomas, 4 renal cell carcinomas and 1 bladder carcinoma) which had bone metastases were treated with eel-calcitonin, Elcitonin injections for relief of bony pain. Forty mgs. of Elcitonin was injected intramuscularly, 2 to 3 times a week, to out-patients. Forty to 80 mgs. of Elcitonin was injected intramuscularly, daily to hospitalized patients. Relief of the pain was obtained in 71.4% of all patients (71.4% of out-patients and 71.4% of hospitalized patients) and especially in 88.9% of prostatic carcinoma patients. Hypercalcemia was seen in only one patient of renal cell carcinoma. It is considered that Elcitonin treatment is useful for relief of bony pain in the patients with bone metastases, with or without hypercalcemia.
 ...
PMID:[Experience of Elcitonin treatment in metastatic bony pain of urological tumors]. 317 47

Salmon calcitonin 100 MRCU/day or a saline placebo were given in daily injections for at least three months to 49 patients with bone metastases from breast cancer in a randomized double-blind trial. All patients were normocalcemic, and most patients had stable or regressing disease at start of trial. No improvement in general performance or bone pain was detected as measured by a visual analogue scale, the daily duration of pain or consumption of analgetic drugs. Calcitonin had no effect on disease progression as judged by bone scans and radiographs. Calcitonin therapy did not affect serum calcium, alkaline phosphatase, bone gla-protein, or the urinary excretion of calcium and hydroxyproline. Serum phosphate and magnesium decreased significantly during calcitonin treatment (p = 0.01, and 0.00005, respectively). It was concluded that salmon calcitonin in this dosage has no discernible effect on skeletal pain, general performance, bone metabolism or disease progression in patients with breast cancer metastatic to bone. A significant decrease in serum phosphate and magnesium probably indicated an effect of calcitonin on the renal excretion of these ions.
 ...
PMID:Evaluation of salmon calcitonin treatment in bone metastases from breast cancer--a controlled trial. 328 58

Osteolytic characteristics of bone metastasis from renal cell carcinoma were morphologically and biochemically investigated. First, undecalcified ground sections of bone metastases were made from four patients with renal cell carcinoma. Second, renal cell carcinoma cell line (RCC-K1) was established from one of the four patients, and its effect on bone resorption in vitro was examined. Marked proliferation and activation of osteoclasts around the tumor cells was histologically demonstrated. Conditioned medium from the RCC-K1 cells contained potent bone-resorbing activity in vitro. The activity was reduced to basal level by calcitonin, but was not blocked by indomethacin. The activity was lost after dialysis (MW cutoff 3500), while it was retained after 2 weeks of storage. Levels of prostaglandin E2 and 1,25-dihydroxyvitamin D of the RCC-K1-conditioned medium were insufficient to cause bone resorption in vitro. The conditioned medium did not stimulate cAMP accumulation in rat osteoblastic cells. These results suggest that renal cell carcinoma causes bone destruction through the stimulation of osteoclasts by locally secreting an unknown humoral factor or factors.
 ...
PMID:Osteoclast-mediated osteolysis in bone metastasis from renal cell carcinoma. 338 23

The analgesic effect of salmon calcitonin (Calcitonina-Sandoz) was evaluated in an open study of thirty-four patients with bone metastases of a lung cancer. Two different administration protocols were used: eighteen subjects received sCT 400 IU/day for three consecutive days, while the remaining sixteen were given sCT 200 IU/day for six consecutive days. In both protocols salmon calcitonin was diluted in saline and infused intravenously in one hour. Bone, visceral and neuritic pain were evaluated by means of Huskisson's visual analog scale and Keele's pain scale. The analgesic efficacy of salmon calcitonin was also evaluated on the basis of daily consumption of analgesic drugs. Salmon calcitonin proved of extreme efficacy in the treatment of intractable pain from advanced malignancy. A higher and earlier analgesic activity was observed with sCT at the 400 IU daily dosage.
 ...
PMID:Salmon calcitonin in cancer pain: comparison between two different treatment schedules. 358 73

Lately it has been reported that calcitonin is effective for the treatment of hypercalcemia and for the relief of pain caused by osteolytic bone metastasis. Thus we have studied the analgesic effect of synthetic eel calcitonin (ECT) on 8 breast cancer patients with bone metastases. ECT was administered in the dose of 20 or 40 I.U. twice a day intramuscularly for 7 days without other antineoplastic treatment, and the laboratory data of its analgesic effect and change has been examined. An analgesic effect was obtained on all 8 patients who had received ECT. However, an improvement of radiological findings of metastatic osteolysis and a decrease in urine hydroxyproline were not found after short term (7 days) treatment with calcitonin. These results suggest that the effect of ECT on the relief from pain due to bone metastasis is not caused by an improvement of the osteolytic metastatic lesions.
 ...
PMID:[The analgesic effect of calcitonin on breast cancer patients with bone metastases]. 361 14

Synthetic Calcitonin Derivative obtained from eel (eel-calcitonin) was given to 15 patients suffering from pain due to bone metastases of malignant tumors. The analgesic effect of synthetic eel-calcitonin derivative was evaluated through pain and narcotic score with the Ridit method. With regard to pain score, significant analgesic effect was observed in the first week (p less than 0.001), and after a month there was also a decrease in the narcotic score (p less than 0.05). However, changes in serum Ca, P, ALP values, and the findings of bone scintigrams and roentgenography, rarely occurred following the treatment. The toxicities of eel-calcitonin which were observed in this series were as follows; nausea and vomiting (33%), flush (11%), eruption (6%). These findings suggest that synthetic eel-calcitonin derivative is a very useful agent for pain due to bone metastases.
 ...
PMID:[Effect of treatment with synthetic eel-calcitonin derivative in patients suffering pain due to bone metastases]. 405 17

We investigated the usefulness and limits of serum thyroglobulin, serum calcitonin, and serum tissue polypeptide antigen as humoral markers for thyroid carcinoma in 364 patients with papillary, follicular, medullary, and undifferentiated types of thyroid cancer. In agreement with other studies we found that serum thyroglobulin was a specific and sensitive marker for well-differentiated thyroid cancer after total thyroidectomy. Lymph node, lung, and bone metastases were associated with high serum thyroglobulin concentrations, both during and after thyroid-suppressive therapy with L-thyroxine. Serum thyroglobulin determination was superior to whole body scanning in predicting the presence of differentiated metastases, because patients with nonfunctioning metastases and negative whole body scan also had high levels of serum thyroglobulin. Serum calcitonin levels were increased in all patients with active medullary thyroid cancer, confirming the specificity of this marker in detecting tumors arising from parafollicular C-cells. Furthermore, in medullary thyroid cancer serum tissue polypeptide antigen levels were also increased in most patients. This last substance was found to be increased also in undifferentiated thyroid cancer. Of particular interest was the finding of increased serum tissue polypeptide antigen levels in 15 cases of differentiated thyroid cancer, whose metastases underwent a progressive process of "dedifferentiation."
 ...
PMID:Humoral markers for thyroid carcinoma. 406 37

48 patients with metastatic breast cancer and extensive bone involvement were treated with salm-calcitonin and polychemo-therapy or hormonal treatment. They were compared with a control group of 73 patients without calcitonin therapy. One third of the patients from the calcitonin group referred pain relief which was obviously independent from the therapy effects of the polychemo or hormonal treatment. Since only subjective criteria for sceletal pains were used and no therapy arm with calcitonin alone was studied, the results of our study have to be critically analyzed together with other reports about calcitonin and bone metastases in the literature.
 ...
PMID:[Calcitonin in bone-metastasizing breast carcinoma. Results of a pilot study]. 620 36


<< Previous 1 2 3 4 5 6 Next >>